Among patients who received adjuvant therapy, those with TNBC had a worse prognosis than those with Luminal A breast cancer, which express ER and/or PR, but not HER2 [27]; however, when analyzing patients who only received surgery and no adjuvant therapy, there was no difference in outcome between the subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.